Subscribe
shutterstock_1652254300_taljat_david
Taljat David / Shutterstock.com
18 April 2023AmericasLiz Hockley

SCOTUS deals fresh blow to Novartis’ MS drug patent

Petition to review invalidation of Gilenya patent denied | Novartis challenged decision resulting from a change in judicial panel.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Why Novartis lost its treatment dispute with Teva
17 January 2023   The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.
Big Pharma
Novartis ‘abused’ discovery process for Zolgensma patent
23 May 2023   Two subsidiaries of the French pharma giant allege ‘wilful’ patent infringement by the Swiss-American pharma firm | Novartis ‘hid’ information in a previous lawsuit relating to spinal muscular atrophy drug used to treat young children.
Generics
Novartis vows to challenge heart drug patent loss
11 July 2023   Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Big Pharma
Why Novartis lost its treatment dispute with Teva
17 January 2023   The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.
Big Pharma
Novartis ‘abused’ discovery process for Zolgensma patent
23 May 2023   Two subsidiaries of the French pharma giant allege ‘wilful’ patent infringement by the Swiss-American pharma firm | Novartis ‘hid’ information in a previous lawsuit relating to spinal muscular atrophy drug used to treat young children.
Generics
Novartis vows to challenge heart drug patent loss
11 July 2023   Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.

More on this story

Big Pharma
Why Novartis lost its treatment dispute with Teva
17 January 2023   The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.
Big Pharma
Novartis ‘abused’ discovery process for Zolgensma patent
23 May 2023   Two subsidiaries of the French pharma giant allege ‘wilful’ patent infringement by the Swiss-American pharma firm | Novartis ‘hid’ information in a previous lawsuit relating to spinal muscular atrophy drug used to treat young children.
Generics
Novartis vows to challenge heart drug patent loss
11 July 2023   Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers